Connect with us

Media & Technology

The Exciting Rise of GenViro; Decision Diagnostics Corp (OTCMKTS: DECN)

Published

on

Decision Diagnostics Corp (OTCMKTS: DECN) is making a powerful move up the charts as the Companies GenViro(TM) Corona Virus Screening Kit continues to gain traction as the Company prepares for U.S. based testing. The GenViro(TM) Corona Virus Screening Kit is a timely, simple to use, cost effective instant test kit that provides results in as little as 10.5 seconds, based on a small finger prick blood sample. The device costs $15 and the test strip kit costs $30. Microcapdaily has been reporting on DECN since the stock was .05.

As coronavirus spreads around the world, safely reopening the country and the world depends almost entirely on testing – widespread, affordable, accurate and accessible testing. Antibody tests and nasal swabs currently on the market are both invasive and take up to weeks for results. DECN many have the solution with its GenViro(TM) Corona Virus Screening Kit. According to CEO Keith Berman its a “game changer. We’re the product of choice because it works, it works fast and because it’s affordable.  That’s why companies are interested. Businesses can test their workers as often as they want, in a matter of seconds, every day if they like,” said Berman.

Decision Diagnostics Corp (OTCMKTS: DECN) is a nationwide prescription and non-prescription diagnostics and home testing products distributor. The Company markets its GenUltimate, GenSure, PetSure (test strips for dogs and cats) and GenChoice (in FDA 510(k) review), its panacea GenUltimate TBG glucose test strips and meter (in 3rd party testing), its GenPrecis test strips and meter (for private label sale), and its GenUltimate 4Pets glucose test strips and meter for the diabetic testing of dogs, cats and horses. Decision Diagnostics is FDA approved and hase complete R&D and manufacturing facilities in South Korea.

DECN'S GenViro!(TM) Corona Virus "Swift" Kit, Now to Be ...Decision Diagnostics introduced its GenViro(TM) Corona Virus Screening Kit in March. The Company stated at the time: Today, in the third discussion of our break-through test for the coronavirus (COVID19), we present the Coronavirus test kit and the Phase 1 unit forecast. The introduction of our new screening methodology for the Coronavirus (Covid19) will provide a timely, simple to use and cost effective solution for the screening of the frightening COVID19 virus. First uses of our kits will be in pharmacies, doctor’s offices, clinics and urgent care centers, and long term care facilities. We anticipate the sale of 420,000,000 kits in the first full year of commercial sale. The company has retained FDA counsel who is in the process of securing expected emergency waiver for diagnostics and diagnostic devices.

GenViro(TM) Corona Virus Screening Kit has been getting noticed by main stream media with CBS New York coverfing it in a segment called: Max Minute: Diabetes Company’s Affordable, Fast Coronavirus Test May Be Key To Reopening Businesses. According to the segment: NEW YORK (CBSNewYork) – “We’re the product of choice because it works, it works fast and because it’s affordable,” According to DECN CEO Keith Berman says of the GenViro(TM) Corona Virus Screening Kit “It works by taking a finger-prick drop of blood and, through sophisticated micro-processing, arrives at a result within 30 to 45 seconds. The device costs $15 and the test strip kit costs $30. That’s why companies are interested. Businesses can test their workers as often as they want, in a matter of seconds, everyday if they like,” said Berman. The segment ends with “It’s not free, but it is an affordable enough technology that could open up restaurants, movies, all manner of businesses and group venues. The company hopes to have all the FDA-mandated testing done by next week. If approved, Berman says they could ship as many as 100,000 units immediately and be making up to 400,000 a week within 60 days.”

To Find out the inside Scoop on DECN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DECN

On August 3 DECN announced its support for the recently issued FDA Covid-19 At-Home Use Template saying it, “Contains much of what was in our May 1st At-Home Application to the FDA.” The company says it is 100 percent behind the issuance of at-home testing guidelines, and that it is now preparing to amend its first EUA submission PEUA200947, for its GenViro! Blood Swift Kit for at-home use. Shortly thereafter we anticipate filing a separate EUA application with the FDA for its GenViro! Saliva Swift Kit for home use. Both applications for the home use of GenViro! Swift are expected to meet the new FDA template, the FDA’s first such template issued by the FDA. No Covid-19 home-based test kits have as yet been authorized by the FDA, although several at-home specimen collection kits have been authorized. Nonetheless, experts universally agree that routine at-home testing of people who may be asymptomatic can be transformative in the effort to significantly slow the spread. Current at-home specimen collection kits do not provide at-home point of care testing.

DECN is currently preparing for U.S. based testing of its COVID-19 test kits. The company just received completed testing from its Korean partner where the required 75 non-infected donors were tested for both blood and saliva (a total of 150). The next step for our partner will be to test known infected samples. These tests will be done in conjunction with a Korean teaching hospital or similar institution. Once completed, this testing data will provide the filing data needed for the anticipated EU CE Mark and registration of our GenViro! Swift kits in other off-shore countries as may be required. In addition, the company has ordered approximately 600 Genviro! Swift testing strips delivered to us in vials for the feasibility rounds of testing in the USA. The company has received the first 300 of these sensors and plans to begin testing for saliva based samples with its chosen U.S. based partner. After this initial USA testing, another 600 test strips for the second, more demanding study.

DECN expects to receive the U.S. supply of production testing samples during the first week of August 2020 which is expected to coincide with the company’s selection of an experienced US based clinical testing partner. The company has narrowed potential US testing partners to two clinical trials organizations and allied laboratories and expects to announce its decision in the next few days. That organization will lead the clinical trials in the U.S. that DECN expects will be the final requirement to secure FDA emergency authorization.

We have a Monster Pick Coming. Subscribe Right Now!

Currently running higher DECN is an exciting story in small caps establishing itself as a volume leader and proven runner. DECN GenViro(TM) Corona Virus Screening Kit provides results in as little as 10.5 seconds, based on a small finger prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19.  DECN is currently preparing for U.S. based testing of its COVID-19 test kits. The company just received completed testing from its Korean partner where the required 75 non-infected donors were tested for both blood and saliva (a total of 150). The next step for our partner will be to test known infected samples. These tests will be done in conjunction with a Korean teaching hospital or similar institution. Once completed, this testing data will provide the filing data needed for the anticipated EU CE Mark and registration of our GenViro! Swift kits in other off-shore countries as may be required. In addition, the company has ordered approximately 600 Genviro! Swift testing strips delivered to us in vials for the feasibility rounds of testing in the USA. Microcapdaily has been reporting on DECN since the stock was .05. We will be updating on DECN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DECN.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in DECN either long or short and we have not been compensated for this article.

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Featured

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) Secure Partnership

Published

on

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan's proprietary target discovery platform.

TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million.

Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease.

All things considered, this is among one of the largest deals you’ll see for a micro-cap biopharma company. As many of you know, companies in this sector of this size and scale are typically not profitable – mainly focusing on R&D until their drug or technology is fully approved/commercially viable. 

The critical thing to note with this deal between TScan and Amgen is that the cash milestones ensure a cash runway for TCRX, potentially even until they become commercially viable and profitable. 

Here’s a breakdown of the press release in layman’s terms, so anyone without background or knowledge in this space can better understand: 

Amgen and TScan Therapeutics are teaming up to find new treatments for Crohn’s disease, a chronic condition that causes inflammation in the gut. TScan has a unique platform called TargetScan that can identify the proteins recognized by the immune system in people with the disease. Amgen will use this information to create new drugs to treat Crohn’s disease.

As part of the deal, TScan will get an upfront payment of $30 million from Amgen and could earn more than $500 million if the collaboration is successful. Amgen will have the rights to develop and sell any new drugs from this partnership.

To Discover the Inside Scoop on TCRX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Both companies will be responsible for their research costs, and Amgen can expand the collaboration to include another condition called ulcerative colitis. This partnership could lead to new and better treatments for people with Crohn’s disease, who currently have limited options for managing their symptoms.

Here are a couple of blurbs from the management team

“Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from inflammatory bowel disease, but often lack efficacy and durability,” said Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen. “TScan’s platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs.”

“We’re excited to apply our target discovery platform to the autoimmunity space,” said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. “Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases.”

What’s retail saying?

As per usual, with gains of around 135%, you can probably guess that retail is all over it. Investors practically all over the internet keep their eye on the stock for potential entry points utilizing various day trading techniques. 

Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. If you look at their chart from the prior months, the average volume was relatively minuscule – sometimes trading as low as 5K shares a day.  Compared to the ~27M shares traded at the time of writing, that’s a massive shift.

We will update you on TCRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with TCRX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

ContraFect Corp (NASDAQ: CFRX): A Low Float Runner

Published

on

On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual.

On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual. Although the surge may be linked to the news from the previous day, it is difficult to determine as there was not much movement on April 26.

However, sometimes it only takes the right attention from investors to create such positive rallies. It is worth noting that $CFRX has a low float of 1.53M, which can lead to extreme volatility and provide retail traders an opportunity to make significant gains.

To Find out the inside Scoop on CFRX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Summary of latest PR on April 26, 2023

ContraFect Corporation is a clinical-stage biotechnology company developing new treatments for antibiotic-resistant infections. They recently announced that they initiated a Phase 1b/2 study to test the safety, drug disposition, and efficacy of their drug candidate, Exebacase, in patients with chronic prosthetic joint infections (PJI) of the knee. The study is in France and is randomized, double-blind, and placebo-controlled, meaning some patients will receive the drug, while others will receive a placebo. The study will have two parts: Part I will evaluate the drug’s efficacy, safety, and pharmacokinetics at an early six-week time point, while Part II will assess the long-term clinical safety and efficacy of the drug for up to two years. The CEO of ContraFect Corporation is optimistic about the potential of Exebacase to replace the current surgical treatment for chronic PJI, which has not shown significant improvement in clinical outcomes in recent decades.

What are retail traders saying?

https://twitter.com/RealWillTopol/status/1651553835801001986?s=20

It is worth noting that there has been some speculation about the events that have unfolded and the underlying factors that have led to them. 

We’ve observed a subset of traders that capitalize on the volatility by adopting a watchful approach towards stocks, including $CFRX, to generate quick profits. 

However, it is essential to exercise caution when considering following their lead, given the high risk associated with their investment strategies and the prevailing market conditions. While we do not typically recommend emulating their investment decisions, it may be an intriguing endeavor for those willing to assume a certain level of financial risk with funds they can afford to lose.

About ContraFect Corp (NASDAQ: CFRX)

ContraFect is a company that focuses on finding new ways to treat life-threatening infections resistant to antibiotics. Antibiotic-resistant infections are responsible for an estimated 700,000 deaths each year worldwide. ContraFect is developing new medical treatments called DLAs that include lysins and amurin peptides. Lysins are antimicrobial proteins that can quickly kill target bacteria, including those in biofilms, and can work with traditional antibiotics. Amurin peptides can fight many antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. ContraFect believes that lysins and amurin peptides will effectively fight antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections. The company has completed a Phase 2 clinical trial for their lead lysin candidate, exebacase, designated by the FDA as a Breakthrough Therapy for treating MRSA bloodstream infections, including right-sided endocarditis, when combined with traditional antibiotics.

We will update you on CFRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with CFRX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Sasin Tipchai from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.